Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 8c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.71), $0.08 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $223.45 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• Shoe Station Group Inc. (SHOE) Tops Q2 EPS by 11c ; Offers Guidance
• Signet Jewelers (SIG) PT Raised to $136 at UBS on Strong Growth Prospects